Hong Yun Ma, Jeeban Das, Conor Prendergast, Dorine De Jong, Brian Braumuller, Jacienta Paily, Sophia Huang, Connie Liou, Anna Giarratana, Mahdie Hosseini, Randy Yeh, Kathleen M Capaccione
Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation...
November 12, 2023: Current Issues in Molecular Biology